Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145978

Pw145978 View Pathway
drug action

Somatostatin Drug Metabolism Action Pathway

Homo sapiens

PW124340

Pw124340 View Pathway
metabolic

Some path

Homo sapiens

PW122143

Pw122143 View Pathway
signaling

Sonic Hedgehog (Shh)

Mus musculus

PW091415

Pw091415 View Pathway
signaling

Sonic Hedgehog (Shh) Pathway

Homo sapiens
Sonic hedgehog is a protein that in humans is encoded by the SHH ("sonic hedgehog") gene.[5] Both the gene and the protein may also be found notated alternatively as "Shh". Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain. Sonic hedgehog is the best established example of a morphogen as defined by Lewis Wolpert's French flag model—a molecule that diffuses to form a concentration gradient and has different effects on the cells of the developing embryo depending on its concentration. SHH remains important in the adult. It controls cell division of adult stem cells and has been implicated in the development of some cancers.

PW132587

Pw132587 View Pathway
metabolic

Sonidegib Drug Metabolism

Homo sapiens
Sonidegib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Sonidegib passes through the liver and is then excreted from the body mainly through the kidney.

PW146011

Pw146011 View Pathway
drug action

Sonidegib Drug Metabolism Action Pathway

Homo sapiens

PW124070

Pw124070 View Pathway
drug action

Sorafenib Action Pathway

Homo sapiens
Sorafenib, marketed as Nexavar, is a drug for the treatment of advanced renal cell carcinoma (primary kidney cancer). It is an inhibitor of the RAF kinase protein and cell surface kinases PDGF-beta receptor, VEGF 2 and 3 receptor (many sources also say VEGFR 1), c-KIT receptor, and FLT-3 receptor. Overall, sorafenib targets the Raf/Mek/Erk pathway. The kinases that are targeting are involved in angiogenesis which reduces blood flow to the tumor and also for genetic transcription for cell proliferation and replication. Sorafenib's mechanism of action works by inhibiting the cell surface kinases, which blocks their signalling to RAF and AKT pathways which are responsible for cell proliferation. C-KIT and FLT-3 on tumor cells are inhibited causing their proliferation to stop and the PDGF and VEGF receptors on endothelial cells are inhibited to stop the growth of new blood vessels that bring blood flow to the tumor. Sorafenib also inhibits RAF1 which is a protein that regulates apoptosis of the cell. With RAF1 blocked, apoptosis is not regulated and can occur. Sorafenib is taken orally in a tablet for and enters the bloodstream through the GI tract to be delivered to the site of action.

PW144523

Pw144523 View Pathway
drug action

Sorafenib Drug Metabolism Action Pathway

Homo sapiens

PW000624

Pw000624 View Pathway
drug metabolism

Sorafenib Metabolism Pathway (old)

Homo sapiens
Sorafenib is a drug that belongs to the antineoplastics drug class, which is the drug class relating to the treatment of cancer, specifically renal, hepatic and thyroid cancers. This drug works by stopping cancerous tumour progress and stopping therapy replication pf potentially malignant cells. It does this by inhibiting protein synthesis, as we will explore in the pathway. Sorafenib is administered orally, in a tablet form taken twice daily without food. Once ingested, sorafenib finds itself in the endoplasmic reticulum membrane , where it inhibits cytochrome P450 2B6, cytochrome P450 2C8, cytochrome P450 2C9 and UDP-glucuronosyltransferase 1-1. Sorafenib is also catalyzed, with the help uridine diphosphate glucuronic acid and the enzyme UDP-glucuronosyltransferase 1-9 to sorafenib b-D-glucuronide with a by-product of uridine 5’-diphosphate. Sorafenib also undergoes a transformation without the use of catalytic enzymes and becomes sorafenib metabolite M4 and subsequently becomes sorafenib metabolite M5. In another reaction, sorafenib teams up with water and oxygen, using cytochrome P450 3A4 to create sorafenib N-oxide and hydrogen peroxide. Sorafenib N-oxide then undergoes two more reactions, one where it becomes sorafenib N-oxide glucuronide, and another where it becomes sorafenib metabolite M1. Sorafenib metabolite M1 is also attached to another reaction, as sorafenib creates sorafenib metabolite M3, sorafenib metabolite M1 is also created from this metabolite.

PW145493

Pw145493 View Pathway
drug action

Sorbitol Drug Metabolism Action Pathway

Homo sapiens